Vir Biotechnology, Inc. reported $69M of revenue over the trailing twelve months. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $69M (to Q4 2025). Net income: −$252M, trailing twelve months to Q2 2026. Free cash flow: −$204M, trailing twelve months to Q2 2026. Operating margin: −21675%, trailing twelve months to Q4 2025.

VIRVir Biotechnology, Inc.

Healthcare

$11.71+126% 1Y

$11.71

$5.1252 weeks$11.78

VIR as reported

Vir Biotechnology, Inc. reported $69M of revenue over the trailing twelve months. 9 reported series are charted on this page, each one as filed.

$69M

Revenue, trailing twelve months · to Q4 2025 · every figure below is as filed, with no scoring applied

Net income: −$252M
Net income · −54% year on year · trailing twelve months to Q2 2026
Free cash flow: −$204M
Free cash flow · −56% year on year · trailing twelve months to Q2 2026
Operating margin: −21675%
Operating margin · trailing twelve months to Q4 2025

Details›

Every series Ryufin has for VIR, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$69M	n/a	Q4 2025
Net income	−$252M	−54%	Q2 2026
EPS	−$1.85	−54%	Q2 2026
Gross margin	98%	n/a	Q2 2025 · 4 quarters behind
Operating margin	−21675%	n/a	Q4 2025
Net margin	−20293%	n/a	Q4 2025
ROE	−50%	n/a	Q2 2026
ROA	−39%	n/a	Q2 2026
Free cash flow	−$204M	−56%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.